Research Article
Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis
Table 1
Sequential treatment strategies.
| First-line TKI | Second-line TKI | Chemotherapy/stem-cell transplantation |
| Chemotherapy | — | — | Imatinib | — | Chemotherapy/stem-cell transplantation | Bosutinib | — | Chemotherapy/stem-cell transplantation | Dasatinib | — | Chemotherapy/stem-cell transplantation | Nilotinib | — | Chemotherapy/stem-cell transplantation | Imatinib | Bosutinib | Chemotherapy/stem-cell transplantation | Imatinib | Dasatinib | Chemotherapy/stem-cell transplantation | Imatinib | Nilotinib | Chemotherapy/stem-cell transplantation | Imatinib | Ponatinib | Chemotherapy/stem-cell transplantation | Bosutinib | Dasatinib | Chemotherapy/stem-cell transplantation | Bosutinib | Nilotinib | Chemotherapy/stem-cell transplantation | Bosutinib | Ponatinib | Chemotherapy/stem-cell transplantation | Dasatinib | Bosutinib | Chemotherapy/stem-cell transplantation | Dasatinib | Nilotinib | Chemotherapy/stem-cell transplantation | Dasatinib | Ponatinib | Chemotherapy/stem-cell transplantation | Nilotinib | Bosutinib | Chemotherapy/stem-cell transplantation | Nilotinib | Dasatinib | Chemotherapy/stem-cell transplantation | Nilotinib | Ponatinib | Chemotherapy/stem-cell transplantation |
|
|
TKI: tyrosine kinase inhibitor. Hydroxyurea.
|